Antidepressant activity of fingolimod in mice

Recent findings indicate that fingolimod, the first oral drug approved for the treatment of multiple sclerosis (MS), acts as a direct inhibitor of histone deacetylases (HDACs) and enhances the production of brain-derived neurotrophic factor (BDNF) in the CNS. Both mechanisms are relevant to the path...

Descripción completa

Detalles Bibliográficos
Autores principales: di Nuzzo, Luigi, Orlando, Rosamaria, Tognoli, Cristina, Di Pietro, Paola, Bertini, Giuseppe, Miele, Jessica, Bucci, Domenico, Motolese, Marta, Scaccianoce, Sergio, Caruso, Alessandra, Mauro, Gianluca, De Lucia, Carmine, Battaglia, Giuseppe, Bruno, Valeria, Fabene, Paolo Francesco, Nicoletti, Ferdinando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492751/
https://www.ncbi.nlm.nih.gov/pubmed/26171219
http://dx.doi.org/10.1002/prp2.135

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492751/
https://www.ncbi.nlm.nih.gov/pubmed/26171219
http://dx.doi.org/10.1002/prp2.135

Ejemplares similares